Spin Me Round: iBio Reemerges as Innovator of Precision Antibody Immunotherapies

GEN EdgeVol. 5, No. 1 TopicsSpin Me Round: iBio Reemerges as Innovator of Precision Antibody ImmunotherapiesIn transitioning from CDMO and cGMP biologics manufacturing to a AI-powered biotechnology company, iBio has changed leadership and location as part of their mission to become a stalwart in developing antibodies for hard-to-drug targetsJonathan D GrinsteinJonathan D GrinsteinSearch for more papers by this authorPublished Online:27 May 2023https://doi.org/10.1089/genedge.5.1.78AboutSectionsView articleView Full TextPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail View articleFiguresReferencesRelatedDetails Volume 5Issue 1Jan 2023 Information© 2023 by GEN PublishingTo cite this article:Jonathan D Grinstein.Spin Me Round: iBio Reemerges as Innovator of Precision Antibody Immunotherapies.GEN Edge.Jan 2023.401-405.http://doi.org/10.1089/genedge.5.1.78Published in Volume: 5 Issue 1: May 27, 2023PDF download